Abstract
We report here on a case of metachronous second primary non-Hodgkin's lymphoma (NHL) that was diagnosed 6 years after performing subtotal gastrectomy for treating early gastric cancer (EGC). The subtype analysis revealed mantle cell lymphoma (MCL) of the blastic variant with a leukemic presentation, which was composed of mixed small and medium-sized cells. The immunohistochemical staining for cyclin-D1 was positive. The cytogenetic study revealed t(4;6). In Korea, the risk of developing a second primary cancer following gastric cancer was reported to be less than 3.4%, and NHL comprised less than 6.3% of this second primary cancer. Furthermore, MCL represents about 2% of all lymphomas in Korea. To the best of our knowledge, this is the first report of metachronous primary MCL with a leukemic presentation following curative resection of EGC.
REFERENCES
1). Eom BW., Lee HJ., Yoo MW, et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol. 2008. 98:106–10.
2). Ryu DD., Um JW., Son GS, et al. Multiple primary malignant tumors in patients with gastric cancer. J Korean Gastric Cancer Assoc. 2003. 3:139–44.
3). Hiyama T., Hanai A., Fujimoto I. Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res. 1991. 82:762–70.
4). Hamaloglu E., Topaloglu S., Ozdemir A., Ozenc A. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol. 2006. 12:3564–74.
5). Prabhash K., Biswas G., Nair R, et al. Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Indian J Gastroenterol. 2006. 25:261–2.
6). Raderer M., Streubel B., Wöhrer S., Chott A. Metachronous gastric MALT lymphoma and early gastric cancer. Ann Oncol. 2006. 17:724.
7). Banks PM., Chan J., Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992. 16:637–40.
8). Wong KF., Chan JK., So JC., Yu PH. Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders. Cancer. 1999. 86:850–7.
9). Bernard M., Gressin R., Lefrère F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001. 15:1785–91.
10). Bosch F., López-Guillermo A., Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998. 82:567–75.
11). Parrens M., Belaud-Rotureau MA., Fitoussi O, et al. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features. Histopathology. 2006. 48:353–62.
12). Oinonen R., Franssila K., Teerenhovi L., Lappalainen K., Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 1998. 34:329–36.
13). Matutes E., Parry-Jones N., Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma. 2004. 45:2007–15.
14). Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol. 2005. 23:6409–14.
15). Nam MH., Woo HY., Park Q, et al. Mantle cell lymphoma/leukemia in bone marrow: lacking evidence of t(11;14). Korean J Clin Pathol. 2001. 21:437–44.